Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 4/20 | 0.36 |
| ▸ | GMNN | O75496 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | BLM | P54132 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | SLC22A16 | Q86VW1 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.34 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8827832 | 1.00 | MAPT (0.39) | MAPTMAPK1LMNAGMNNNPSR1 | |
| SCHEMBL1902716 | 0.98 | MAPT (0.36) | MAPTMAPK1LMNAGMNNNPSR1 | |
| SCHEMBL570499 | 0.98 | MAPT (0.36) | MAPTMAPK1LMNAGMNNNPSR1 | |
| Iodide SCHEMBL608287 | 0.96 | MAPT (0.35) | MAPTMAPK1LMNAGMNNNPSR1 | |
| SCHEMBL1057053 | 0.82 | MAPT (0.39) | MAPTMAPK1LMNAGMNNNPSR1 | |
| SCHEMBL8055941 | 0.82 | MAPT (0.39) | MAPTMAPK1LMNAGMNNNPSR1 | |
| Iodide SCHEMBL5144330 | 0.80 | MAPT (0.38) | MAPTLMNAMEN1BLMKMT2A | |
| Hydrochloric Acid SCHEMBL1276371 | 0.75 | MAPT (0.45) | MAPTLMNAMEN1BLMKMT2A | |
| Hydrochloric Acid SCHEMBL8672876 | 0.75 | MAPT (0.45) | MAPTLMNAMEN1BLMKMT2A | |
| SCHEMBL6153646 | 0.73 | MAPT (0.41) | MAPTLMNAMEN1BLMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025071519-A1 | A FORMULATION FOR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE | T.C. USKUDAR UNIVERSITESI (TR) | 2025-04-03 | — | — | WO | disclosed |
| US-12121555-B1 | Method for inhibiting enzyme activity using Boscia senegalensis | King Faisal University (SA) | 2024-10-22 | — | — | US | disclosed |
| US-11643395-B2 | Derivatives of 4-aminoantipyrine as anti-Alzheimers butyrylcholinesterase inhibitors | SIDDIQUI HINA (PK) | 2023-05-09 | — | — | US | disclosed |
| US-20210363108-A1 | Derivatives of 4-aminoantipyrine as anti-Alzheimers butyrylcholinesterase inhibitors | SIDDIQUI HINA (PK) | 2021-11-25 | — | — | US | disclosed |
| CN-111566081-B | Bisamide compound and preparation method and application thereof | 天津安百胜医疗科技有限公司 | 2021-04-06 | — | — | CN | disclosed |
| CN-111566081-A | Bisamide compound and preparation method and application thereof | 江苏达骏生物科技有限公司 | 2020-08-21 | — | — | CN | disclosed |
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-25 | — | — | US | disclosed |
| EP-1640021-A1 | PREVENTIVE/REMEDY FOR URINARY DISTURBANCE | Takeda Pharmaceutical Company Limited (JP) | 2006-03-29 | — | — | EP | disclosed |
| EP-0533283-B1 | Assay for serum cholinesterase acitivity | JOHNSON & JOHNSON CLIN DIAG (US) | 1996-12-11 | — | — | EP | disclosed |
| US-5272061-A | Assay for serum cholinesterase activity | EASTMAN KODAK COMPANY (US) | 1993-12-21 | — | — | US | disclosed |
| EP-0533283-A1 | Assay for serum cholinesterase acitivity | Johnson & Johnson Clinical Diagnostics, Inc. (US) | 1993-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021391-A1 | Preventive/remedy for urinary disturbance | ACHE, BCHE, CHAT | MAPT 2484/4885MAPK1 3860/4885LMNA 2527/4885 |
| US-20210363108-A1 | Derivatives of 4-aminoantipyrine as anti-Alzheimers butyrylcholinesterase inhibitors | ACHE, BCHE, BACE1 | MAPT 133/4885MAPK1 2131/4885LMNA 3151/4885 |
| US-11643395-B2 | Derivatives of 4-aminoantipyrine as anti-Alzheimers butyrylcholinesterase inhibitors | ACHE, BCHE, BACE1 | MAPT 133/4885MAPK1 2131/4885LMNA 3151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.